suggests that oncogenic Fibroblast Growth Factor Receptor 2(FGFR2) signaling drives NF-κB-dependent glycolysis in intrahepatic cholangiocarcinoma and that metabolic reprogramming in response to FGFR inhibition confers new targetable vulnerabilities (57). The gene discussed is FGFR2; the disease is cholangiocarcinoma.